RBP4 and myeloid sarcoma: In the subjects without MS at baseline, we found that an elevated RBP4 level at baseline was an independent predictor for incident MS upon follow-up (OR per 10 μg/ml (approximately 1 SD at baseline) increase 1.68, [95% CI 1.22–2.34], P = 0.002 after adjustment for age, gender, puberty, BMI, physical activity and dietary intake at baseline; Model 2; Table 3; Fig. 2).